558. Implementation and Outcomes of a COVID-19 Monoclonal Antibody Treatment Program in an Urban Safety-net Community Hospital

BACKGROUND: Neutralizing monoclonal antibodies (mAbs) bind to the receptor binding domain of the spike protein of SARS-CoV-2. In November 2020, several mAbs were issued an EUA by the FDA as single-dose intravenous (IV) infusions for treatment of mild to moderate COVID-19. mABs were allocated to loca...

Descripción completa

Detalles Bibliográficos
Autores principales: Mena Lora, Alfredo J, Echeverria, Stephanie L, Herald, Fischer, McSweeney, James, Gumasana, Harshil, Burgos, Rodrigo M, Borgetti, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690739/
http://dx.doi.org/10.1093/ofid/ofab466.756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8690739/
http://dx.doi.org/10.1093/ofid/ofab466.756

Ejemplares similares